Literature DB >> 3001680

Immunohistochemical demonstration of carcinoembryonic antigen (CEA) in 120 mammary carcinomas and its correlation with tumor type, grading, staging plasma-CEA, and biochemical receptor status.

W Böcker, G Schweikhart, K Pollow, R Kreienberg, A Klaubert, S Schröder, M Mitze, J Bahnsen, H E Stegner.   

Abstract

Antisera to CEA were used for the immunohistochemical localization and quantification of this antigen in 120 Bouin-fixed, paraffin embedded mammary carcinomas. These results were compared to tumor type, grading, staging, biochemical receptor status, cytosolic CEA-levels of the same tumors, and preoperative plasma CEA-levels. Mammary carcinomas were usually characterized by a low percentage of CEA-positive tumor cells: 50.9% of the cases contained more than 5% CEA-positive tumor cells and were therefore defined as being CEA-histopositive in this study. A relation could be shown between CEA-histopositivity and the histologic tumor type. The majority of invasive lobular carcinomas, tubular, and cribriform carcinomas was CEA-negative (72%). Conversely, 70% of invasive ductal carcinomas were CEA-positive. There was a significantly higher percentage of CEA-histopositivity in grade III tumors than in grade I/II carcinomas. The results obtained by quantification of the immunohistochemical staining of CEA were positively correlated with the results obtained by cytosolic CEA-assay. The overall concordance between tissue and plasma determinations of CEA was found to be 57.1%. A positive trend could be found between CEA-positivity and staging. However, no correlation was observed between CEA-positivity and estrogen receptor status.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3001680     DOI: 10.1016/s0344-0338(85)80010-8

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  4 in total

1.  Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.

Authors:  Caroline Rousseau; David M Goldenberg; Mathilde Colombié; Jean-Charles Sébille; Philippe Meingan; Ludovic Ferrer; Pierre Baumgartner; Evelyne Cerato; Damien Masson; Mario Campone; Aurore Rauscher; Vincent Fleury; Catherine Labbe; Alain Faivre Chauvet; Jean-Sebastien Fresnel; Claire Toquet; Jacques Barbet; Robert M Sharkey; Loic Campion; Françoise Kraeber-Bodéré
Journal:  J Nucl Med       Date:  2020-03-13       Impact factor: 10.057

2.  The immunohistochemical reactivity of a new anti-epithelial monoclonal antibody (MAb b-12) against breast carcinoma and other normal and neoplastic human tissues.

Authors:  H R Zenklusen; C Stähli; F Gudat; J von Overbeck; J Rolink; P U Heitz
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

3.  Diagnostic ability of different human milk fat globule antigens in breast cancer.

Authors:  R L Ceriani; E W Blank; E H Rosenbaum; D Ben Zeev; R S Lowitz; L Johansen; T Trujillo
Journal:  Breast Cancer Res Treat       Date:  1990-05       Impact factor: 4.872

4.  Expression of monoclonal-antibody-defined antigens in fractions isolated from human breast carcinomas and patients' serum.

Authors:  M V Croce; M R Price; A Segal-Eiras
Journal:  Cancer Immunol Immunother       Date:  1995-02       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.